SCHEMBL72220

SCHEMBL72220

CCOC(=O)c1cc(-c2ccccc2OCc2ccccc2)on1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.66
MAPT P10636 4/20 0.55
ALDH1A1 P00352 4/20 0.55
HPGD P15428 3/20 0.52
HSD17B10 Q99714 2/20 0.52
KDM4E B2RXH2 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
THRB P10828 2/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
LMNA P02545 1/20 0.50
GAA P10253 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
ALOX15 P16050 1/20 0.49
PTGER1 P34995 1/20 0.49
PPIA P62937 1/20 0.47
CNR2 P34972 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6817968 0.90 MAPT (0.58) BRD4MAPTALDH1A1HPGDHSD17B10
SCHEMBL6818513 0.89 MAPT (0.54) BRD4MAPTALDH1A1HPGDHSD17B10
SCHEMBL7072565 0.89 ALDH1A1 (0.53) BRD4MAPTALDH1A1HPGDHSD17B10
SCHEMBL12939033 0.86 MAPT (0.56) BRD4MAPTALDH1A1KDM4ETHRB
SCHEMBL2945376 0.86 MAPT (0.49) BRD4MAPTALDH1A1HPGDHSD17B10
SCHEMBL1578001 0.86 MAPT (0.56) BRD4MAPTALDH1A1KDM4ETHRB
SCHEMBL71318 0.85 BRD4 (0.67) BRD4MAPTALDH1A1HPGDHSD17B10
SCHEMBL12939111 0.85 MAPT (0.48) BRD4MAPTALDH1A1HPGDHSD17B10
SCHEMBL2356337 0.85 MAPT (0.48) BRD4MAPTALDH1A1THRBLMNA
SCHEMBL6813770 0.84 MAPT (0.57) MAPTALDH1A1HPGDHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129376-B2 Piperidine derivatives as inhibitors of stearoyl-CoA desaturase AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-03-06 US disclosed
EP-2268143-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE Forest Laboratories Holdings Limited (BM) 2011-01-05 EP disclosed
WO-2009117676-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 WO disclosed
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE SCD, SCD5, FADS2 BRD4 204/4885MAPT 3456/4885ALDH1A1 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.